Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease events
Antonella d’Arminio Monforte(University of Milan), Caroline Sabin(Primary Health Care), Andrew Phillips(Wake Forest University), Wafaa El‐Sadr(Columbia University Irving Medical Center), Ole Kirk(University of Copenhagen), Signe Westring Worm(University of Copenhagen), François Dabis(Université de Bordeaux), Christian Pradier(Université Côte d'Azur), Rainer Weber(Georg Simon Ohm University of Applied Sciences Nuremberg), Matthew Law(UNSW Sydney), Jens Lundgren(Centre of Excellence for Health, Immunity and Infections), Peter Reiss(Amsterdam Institute for Global Health and Development), Stéphane De Wit(Centre Hospitalier Universitaire de Saint-Pierre), Lene Ryom(University of Copenhagen)
Cited by 108
Related Papers
Antiretroviral Treatment of Adult HIV Infection
|JAMA|2012|2.5k
Industrial enzyme applications
|Current Opinion in Biotechnology|2002|1.5k
Decline in the AIDS and death rates in the EuroSIDA study: an observational study
|The Lancet|2003|1.2k
Plasma Levels of Soluble CD14 Independently Predict Mortality in HIV Infection
|The Journal of Infectious Diseases|2011|1.1k